Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.59 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.58 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.58 |
| ▸ | LDLR | P01130 | 2/20 | 0.57 |
| ▸ | KIT | P10721 | 2/20 | 0.57 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.57 |
| ▸ | BCR | P11274 | 6/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | YES1 | P07947 | 1/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
| ▸ | HCK | P08631 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | FRK | P42685 | 1/20 | 0.56 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211923 | 1.00 | ABL1 (0.59) | ABL1MAPK14MAP3K20NR2E1EPHB2 | |
| SCHEMBL24071030 | 0.86 | ABL1 (0.57) | ABL1MAPK14MAP3K20NR2E1EPHB2 | |
| SCHEMBL30340074 | 0.86 | ABL1 (0.57) | ABL1MAPK14MAP3K20NR2E1EPHB2 | |
| SCHEMBL30211927 | 0.85 | DDR1 (0.65) | ABL1MAPK14MAP3K20NR2E1EPHB2 | |
| SCHEMBL24070143 | 0.85 | DDR1 (0.65) | ABL1MAPK14MAP3K20NR2E1EPHB2 | |
| SCHEMBL24070682 | 0.83 | MAPK14 (0.69) | ABL1MAPK14MAP3K20NR2E1EPHB2 | |
| SCHEMBL30211931 | 0.83 | NR2E1 (0.58) | ABL1MAPK14MAP3K20NR2E1EPHB2 | |
| SCHEMBL24070501 | 0.83 | NR2E1 (0.58) | ABL1MAPK14MAP3K20NR2E1EPHB2 | |
| SCHEMBL30447296 | 0.83 | MAPK14 (0.69) | ABL1MAPK14MAP3K20NR2E1EPHB2 | |
| SCHEMBL29515118 | 0.82 | DDR1 (0.78) | ABL1KITBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | claimed |
| CN-115697485-A | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-02-03 | — | — | CN | claimed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| CN-115697485-A | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021239643-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | DDR2, DDR1, DDRGK1 | ABL1 399/4885MAPK14 2850/4885MAP3K20 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.